Latest publications

Cuperus E, Sigurdsson V, Van den Akker PC, Bolling MC, Van Gijn ME, Pasmans SGMA et al. J Dtsch Dermatol Ges 2021 Apr; 19(4):611-614

Nomenclature and clinical phenotypes of atopic dermatitis. Girolomoni G, De Bruin-Weller M, Aoki V, Kabashima K, Deleuran M, Puig L et al. Ther Adv Chronic Dis 2021; 12:20406223211002979

High discordance rate in assessing sentinel node positivity in cutaneous melanoma: Expert review may reduce unjustified adjuvant treatment. El Sharouni MA, Laeijendecker AE, Suijkerbuijk KP, Witkamp AJ, Sigurdsson V, Van Diest PJ et al. Eur J Cancer 2021 Apr 10; 149:105-113

Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts. Ring J, Worm M, Wollenberg A, Thyssen JP, Jakob T, Klimek L et al. J Eur Acad Dermatol Venereol 2021 Mar 22

Fructo-Oligosaccharides Modify Human DC Maturation and Peanut-Induced Autologous T-Cell Response of Allergic Patients . Hayen SM, Knulst AC, Garssen J, Otten HG, Willemsen LEM et al. Front Immunol 2020; 11:600125

Predicting sentinel node positivity in melanoma patients: external validation of a risk-prediction calculator (the MIA nomogram) using a large European population-based patient cohort. El Sharouni MA, Varey AHR, Witkamp AJ, Ahmed T, Sigurdsson V, Van Diest PJ et al. Br J Dermatol 2021 Mar 03

Early and long-term effects of dupilumab treatment on circulating T-cell functions in moderate-to-severe atopic dermatitis patients. Bakker DS, Van der Wal MM, Heeb LEM, Giovannone B, Asamoah M, Delemarre EM et al. J Invest Dermatol 2021 Feb 18

Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. El Sharouni MA, Ahmed T, Varey AHR, Elias SG, Witkamp AJ, Sigurdsson V et al. J Clin Oncol 2021 Apr 10; 39(11):1243-1252

European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics. Thyssen JP, Vestergaard C, Barbarot S, De Bruin-Weller MS, Bieber T, Taieb A et al. J Eur Acad Dermatol Venereol 2021 Feb 15

Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. Beck LA, Thaçi D, Deleuran M, De Bruin-Weller M, Chen Z, Khokhar FA et al. J Dermatolog Treat 2021 Feb 08:1-9

Identification and Purification of Novel Low-Molecular-Weight Lupine Allergens as Components for Personalized Diagnostics. Jappe U, Karstedt A, Warneke D, Hellmig S, Böttger M, Riffelmann FW et al. Nutrients 2021 Jan 28; 13(2)

Accidental food-allergic reactions are associated with higher costs and more sick leave but not with quality of life. Versluis A, Knulst AC, Michelsen-Huisman AD, Houben GF, Blom WM, Le TM et al. Clin Exp Allergy 2021 Apr; 51(4):627-630

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G et al. Acta Derm Venereol 2021 Feb 17; 101(2):adv00402

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. Bansal A, Simpson EL, Paller AS, Siegfried EC, Blauvelt A, De Bruin-Weller M et al. Am J Clin Dermatol 2021 Jan; 22(1):101-115

Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. Bruin-Weller M, Pink AE, Patrizi A, Gimenez-Arnau AM, Agner T, Roquet-Gravy PP et al. J Dermatolog Treat 2021 Mar; 32(2):164-173